Results 131 to 140 of about 15,844 (160)

Predicting hormone receptor status in tumors: An innovative approach using breast ultrasound-radiomics combined model. [PDF]

Medicine (Baltimore)
Yin X, Wang Z, Zhao Q, Zhang X, Sang T, Shao C.   +5 more
europepmc   +1 more source

Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report. [PDF]

Medicine (Baltimore)
Bao X, Chen Z, Xiong J, Yang Z, Zhang N.
europepmc   +1 more source

Historical Perspective of HER2 Testing and Treatment in Prostate Cancer. [PDF]

Curr Oncol
Zamalloa N, Rose J, Lap CJ, Rajendran R, Estephan F, Jatwani K, Poudel A, Subrahmanyam R, Hurley PJ, Nava VE, Jain M.   +10 more
europepmc   +1 more source

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. [PDF]

ESMO Open
Pascual T, Villacampa G, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Villanueva L, Gonzalez-Rodriguez M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Ferrero-Cafiero JM, González-Farré X, Villagrasa P, Prat A, Ciruelos E.   +23 more
europepmc   +1 more source

Mechanisms responsible for ERBB2 gene overexpression in human breast and non-breast cancer cells. The role of AP-2 transcription factors [PDF]

, 2005
Begon, Dominique Y, Delacroix, Laurence, Jackers, Pascale, Vernimmen, Douglas, Winkler, Rosita   +4 more
core  

Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension. [PDF]

J Am Heart Assoc
Wu W, Kong F, Chen Z, Huang L, Nie X, Bian JS.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Gastroenterology, 2017
Drugs that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) are the standard treatment of patients with different types of cancer, including HER2-overexpressing gastroesophageal tumors. Unfortunately, cancer cells become resistant to these drugs, so overall these drugs provide little benefit to patients with these tumors.
Anne Steins, Kausilia K Krishnadath, Louis Vermeulen   +2 more
exaly   +3 more sources

Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival

The American Journal of Pathology, 2023
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, currently untreatable Schwann cell-derived neoplasms with hyperactive mitogen-activated protein kinase and mammalian target of rapamycin signaling pathways. To identify potential therapeutic targets, previous studies used genome-scale shRNA screens that implicated the neuregulin-1 ...
Laurel E. Black, Jody F. Longo, Joshua C. Anderson, Steven L. Carroll   +3 more
openaire   +2 more sources

Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/β-catenin signaling pathway in vitro

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021
B, Liu, T, Gao, H Y, Wu, M, Wan
openaire   +2 more sources

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases

Molecular Cell, 2020
Joshua B Sheetz, Sebastian Mathea, Hanna Karvonen   +2 more
exaly